FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551846360> ?p ?o ?g. }

• W2551846360 abstract "Abstract Abstract 964 Background: High dose immunosuppressive therapy and hematopoietic stem cell transplantation (HSCT) has shown efficacy in severe or rapidly progressive systemic sclerosis (SSc) in phase 1 and 2 trials with durable responses in two thirds of patients (pts), while a recent phase 2 randomised trial in 19 SSc pts showed superior benefit of HSCT over iv pulse cyclophosphamide (Cy) on skin score and lung function. Methods: The ASTIS-trial (Autologous Stem cell Transplantation International Scleroderma trial) is a multinational prospective randomized controlled phase 3 trial, comparing safety and efficacy of HSCT versus Cy in early progressive dcSSc pts with disease duration of a) 4 years or less and evidence of organ involvement or b) of 2 years or less and evidence of systemic inflammation with or without major organ involvement. Major exclusion criteria were: concomitant severe SSc disease (mean PAP > 50 mmHg, DLCO < 40% predicted, creatinine clearance (CCl) <40 ml/min, LVEF <45%, uncontrolled arythmia, infection, previous Cy (>5gr iv or >3months oral) treatment), liver failure. Pts randomized to the transplant arm underwent mobilization with Cy 2×2 g/m2 + G-CSF 10mcg/kg/d, conditioning with Cy 200 mg/kg, rbATG 7.5 mg/kg, followed by reinfusion of CD34+ autologous HSCT. Controls were treated with 12× monthly iv pulse Cy 750 mg/m2. Crossing over was allowed after 2 years. The primary endpoint was event-free survival (EFS), defined as survival until death or development of major organ failure at 2 yrs. Toxicity according to WHO criteria and progression free survival (defined as worsening of modified Rodnan skin score, functional ability, major organ function) were the main secondary endpoints. The effects of treatment were analyzed on an ITT basis and by comparing EFS using the KM survival curves (using log-rank test) and Cox models. Results: 156 pts (female 59%), from 27 centers were enrolled in 10 countries from March 2001 until October 2009 and randomized to HSCT (n=79) or iv pulse Cy (n=77). Seventy-five pts in each arm started treatment, 70 pts in HSCT and 58 pts in control groups completed treatment. The median time (Interquartile Range (IR)) from randomization to completion of treatment was 93 (43.0) days in the HSCT and 338 (41.75) days in the control groups respectively. Baseline characteristics (mean (SD)) of the pts were: age 44 (11.2) yrs, SSc duration 1.4 (1.3) yrs, BMI 24 (14.4), Rodnan skin score 25 (8), HAQ 1.35 (0.8), prior Cy therapy 22%, creat cl 116 (39.5) ml/min, LVEF 65% (8.5), DLCO 59% (14), with no significant differences between the 2 arms. With data cut at 1 May 2012, median follow-up (IR) are 33 (42.0) and 27 (34.0) months in the HSCT and control groups respectively. Forty two events occurred : 18 in the HSCT group (16 deaths and 2 irreversible renal failures) and 24 in the control group (24 deaths). Event-free survival was time-dependent with a hazard ratio at 84 months of 0.22 (95% CI 0.08–0.58, P= 0.002). Eight deaths (including 1 during mobilization and 1 after conditioning) in the HSCT group were deemed treatment-related by the independent data monitoring committee with heart failure (3), ARDS (2), multiple organ failure (2) and pulmonary oedema (1) as the causes of death. In the control group, none died from treatment causes and most deaths were due to progressive disease. Eight pts in the control arm received rescue HSCT treatment, one of whom later died from secondary acute myeloid leukaemia. Two HSCT pts received rescue iv Cy therapy. Conclusions: The ASTIS-trial is the first international, investigator-initiated, phase 3 HSCT trial in early diffuse cutaneous systemic sclerosis. The data show that despite 10% treatment-related mortality, long term event-free survival and overall survival were better in the HSCT group than in the group treated with iv pulse cyclophosphamide. (Funded by the European Group for Blood and Marrow Transplantation, European League Against Rheumatism, AP-HP, NIHR, DIGR, Imtix-Sangstat, Miltenyi-Biotec, Amgen Europe; Current Controlled Trials number, ISRCTN 54371254). Disclosures: No relevant conflicts of interest to declare." @default.
• W2551846360 created "2016-11-30" @default.
• W2551846360 creator A5001572586 @default.
• W2551846360 creator A5002561882 @default.
• W2551846360 creator A5003652734 @default.
• W2551846360 creator A5006123817 @default.
• W2551846360 creator A5006190744 @default.
• W2551846360 creator A5006659055 @default.
• W2551846360 creator A5007005611 @default.
• W2551846360 creator A5008642034 @default.
• W2551846360 creator A5009704675 @default.
• W2551846360 creator A5010063238 @default.
• W2551846360 creator A5012296122 @default.
• W2551846360 creator A5012691135 @default.
• W2551846360 creator A5013460374 @default.
• W2551846360 creator A5014020914 @default.
• W2551846360 creator A5014740818 @default.
• W2551846360 creator A5018678002 @default.
• W2551846360 creator A5018974718 @default.
• W2551846360 creator A5020333191 @default.
• W2551846360 creator A5021291065 @default.
• W2551846360 creator A5023094354 @default.
• W2551846360 creator A5027096828 @default.
• W2551846360 creator A5027562477 @default.
• W2551846360 creator A5032056056 @default.
• W2551846360 creator A5032815689 @default.
• W2551846360 creator A5033331730 @default.
• W2551846360 creator A5042472856 @default.
• W2551846360 creator A5045260727 @default.
• W2551846360 creator A5045591880 @default.
• W2551846360 creator A5047159099 @default.
• W2551846360 creator A5048105812 @default.
• W2551846360 creator A5050538063 @default.
• W2551846360 creator A5051159361 @default.
• W2551846360 creator A5057152129 @default.
• W2551846360 creator A5058415753 @default.
• W2551846360 creator A5060016483 @default.
• W2551846360 creator A5066746482 @default.
• W2551846360 creator A5068412969 @default.
• W2551846360 creator A5072582820 @default.
• W2551846360 creator A5074400852 @default.
• W2551846360 creator A5074627741 @default.
• W2551846360 creator A5079255115 @default.
• W2551846360 creator A5083956139 @default.
• W2551846360 creator A5087331994 @default.
• W2551846360 creator A5091416702 @default.
• W2551846360 date "2012-11-16" @default.
• W2551846360 modified "2023-10-18" @default.
• W2551846360 title "Autologous Hematopoietic Stem Cell Transplantation Versus Intravenous Pulse Therapy Cyclophosphamide for Severe or Rapidly Progressive Systemic Sclerosis, the Astis Trial" @default.
• W2551846360 doi "https://doi.org/10.1182/blood.v120.21.964.964" @default.
• W2551846360 hasPublicationYear "2012" @default.
• W2551846360 type Work @default.
• W2551846360 sameAs 2551846360 @default.
• W2551846360 citedByCount "4" @default.
• W2551846360 countsByYear W25518463602013 @default.
• W2551846360 countsByYear W25518463602014 @default.
• W2551846360 countsByYear W25518463602019 @default.
• W2551846360 crossrefType "journal-article" @default.
• W2551846360 hasAuthorship W2551846360A5001572586 @default.
• W2551846360 hasAuthorship W2551846360A5002561882 @default.
• W2551846360 hasAuthorship W2551846360A5003652734 @default.
• W2551846360 hasAuthorship W2551846360A5006123817 @default.
• W2551846360 hasAuthorship W2551846360A5006190744 @default.
• W2551846360 hasAuthorship W2551846360A5006659055 @default.
• W2551846360 hasAuthorship W2551846360A5007005611 @default.
• W2551846360 hasAuthorship W2551846360A5008642034 @default.
• W2551846360 hasAuthorship W2551846360A5009704675 @default.
• W2551846360 hasAuthorship W2551846360A5010063238 @default.
• W2551846360 hasAuthorship W2551846360A5012296122 @default.
• W2551846360 hasAuthorship W2551846360A5012691135 @default.
• W2551846360 hasAuthorship W2551846360A5013460374 @default.
• W2551846360 hasAuthorship W2551846360A5014020914 @default.
• W2551846360 hasAuthorship W2551846360A5014740818 @default.
• W2551846360 hasAuthorship W2551846360A5018678002 @default.
• W2551846360 hasAuthorship W2551846360A5018974718 @default.
• W2551846360 hasAuthorship W2551846360A5020333191 @default.
• W2551846360 hasAuthorship W2551846360A5021291065 @default.
• W2551846360 hasAuthorship W2551846360A5023094354 @default.
• W2551846360 hasAuthorship W2551846360A5027096828 @default.
• W2551846360 hasAuthorship W2551846360A5027562477 @default.
• W2551846360 hasAuthorship W2551846360A5032056056 @default.
• W2551846360 hasAuthorship W2551846360A5032815689 @default.
• W2551846360 hasAuthorship W2551846360A5033331730 @default.
• W2551846360 hasAuthorship W2551846360A5042472856 @default.
• W2551846360 hasAuthorship W2551846360A5045260727 @default.
• W2551846360 hasAuthorship W2551846360A5045591880 @default.
• W2551846360 hasAuthorship W2551846360A5047159099 @default.
• W2551846360 hasAuthorship W2551846360A5048105812 @default.
• W2551846360 hasAuthorship W2551846360A5050538063 @default.
• W2551846360 hasAuthorship W2551846360A5051159361 @default.
• W2551846360 hasAuthorship W2551846360A5057152129 @default.
• W2551846360 hasAuthorship W2551846360A5058415753 @default.
• W2551846360 hasAuthorship W2551846360A5060016483 @default.
• W2551846360 hasAuthorship W2551846360A5066746482 @default.
• W2551846360 hasAuthorship W2551846360A5068412969 @default.
• W2551846360 hasAuthorship W2551846360A5072582820 @default.
• W2551846360 hasAuthorship W2551846360A5074400852 @default.
• W2551846360 hasAuthorship W2551846360A5074627741 @default.
• W2551846360 hasAuthorship W2551846360A5079255115 @default.
• W2551846360 hasAuthorship W2551846360A5083956139 @default.

• next